In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide ...

Mawari, a pioneer in real‑time delivery of AI‑driven immersive 3D experiences, today unveiled its public Guardian Node Offering under the Decentralized Infrastructure Offering (DIO) model. The ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...